Imapextide

What is Imapextide?

Imapextide (development code MBX-1416) is MBX Biosciences' investigational GLP-1 receptor antagonist for post-bariatric hypoglycemia (PBH). Like avexitide (Amylyx/formerly Eiger), imapextide blocks GLP-1 receptor activation to prevent the inappropriate insulin spikes that drive reactive hypoglycemia in patients who have undergone Roux-en-Y gastric bypass. The key differentiator is dosing interval — imapextide is engineered as a sustained-action analog suitable for once-weekly subcutaneous administration, versus avexitide's twice- or three-times-daily schedule. The 2025 J Clin Endocrinol Metab Phase 1 study (Davenport et al.) characterized the sustained pharmacological activity in healthy volunteers, with weekly dosing producing durable GLP-1 receptor blockade. Phase 2 development in PBH is ongoing.

What Imapextide Is Investigated For

Imapextide is positioned in the same therapeutic niche as avexitide — GLP-1 receptor antagonism for severe symptomatic post-bariatric hypoglycemia — but with substantially improved dosing convenience through engineered sustained action supporting once-weekly subcutaneous administration. The strongest evidence is the 2025 J Clin Endocrinol Metab Phase 1 pharmacokinetic and pharmacodynamic study in healthy volunteers, demonstrating durable GLP-1 receptor blockade over a week following a single subcutaneous dose. Phase 2 PBH efficacy trials are ongoing as of mid-2026. The honest caveats: imapextide has not yet been demonstrated in PBH patients in Phase 2/3 efficacy trials at the time of writing, and the question of whether once-weekly dosing produces equivalent symptomatic PBH benefit to the multiple-daily-dose avexitide regimen has not been answered. Imapextide and avexitide are pharmacologically similar mechanism-of-action competitors in a small but clinically important PBH market.

History & Discovery

Imapextide emerged from MBX Biosciences' peptide engineering platform, with the company positioning the molecule as a successor to short-acting GLP-1 receptor antagonists (avexitide and the underlying exendin-(9-39) chemistry) for post-bariatric hypoglycemia. MBX took the molecule through Phase 1 healthy-volunteer studies in 2023–2024, with results published in the Journal of Clinical Endocrinology & Metabolism in 2025 demonstrating sustained pharmacological activity over a week following a single subcutaneous dose. Phase 2 PBH efficacy trials are ongoing as of mid-2026. The competitive positioning is direct against avexitide: same target (GLP-1 receptor), same indication (PBH), but materially better dosing interval. Whether the once-weekly profile translates to comparable PBH symptomatic benefit, the key clinical question, will be answered in Phase 2 trials.

How It Works

Imapextide is a once-weekly injection that blocks the GLP-1 receptor — preventing the inappropriate insulin spikes that cause dangerous low blood sugar after gastric bypass surgery. By blocking this receptor, the meal-induced insulin release stays at normal levels instead of going into overdrive, preventing the hypoglycemic crash that follows. The key advantage over earlier GLP-1 antagonists is that one weekly injection covers the entire week instead of needing 2-3 daily injections.

Imapextide is engineered for sustained pharmacological activity — likely through fatty acid attachment or alternative chemistry approaches that extend plasma half-life and tissue residence. It competitively binds the GLP-1 receptor without activating it, preventing endogenous GLP-1 from amplifying glucose-stimulated insulin secretion at pancreatic beta cells. In post-bariatric hypoglycemia, the underlying pathophysiology is exaggerated postprandial GLP-1 release from L-cells (driven by rapid delivery of nutrients to the distal small bowel after Roux-en-Y gastric bypass), producing hyperinsulinemia disproportionate to the glycemic load and reactive hypoglycemia within 1–3 hours of eating. Imapextide blocks the amplification step. The once-weekly dosing means a single injection produces continuous GLP-1 receptor blockade across the meal-induced GLP-1 surges throughout the week. The sustained-action property is the key engineering differentiator versus avexitide (which has a short subcutaneous half-life requiring twice- or three-times-daily dosing). The Phase 1 pharmacodynamic study confirmed that weekly subcutaneous imapextide produces measurable GLP-1 receptor blockade over the dosing interval.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Imapextide:

• 01Phase 2 efficacy in PBH patients — not yet published.
• 02Head-to-head versus avexitide — direct comparison has not been performed.
• 03Long-term safety beyond Phase 1 healthy-volunteer studies.
• 04Use in congenital hyperinsulinism — extrapolation from avexitide CHI evidence is plausible but not validated for imapextide.
• 05Pregnancy and pediatric use — not characterized.

Forms & Administration

Once-weekly subcutaneous injection. Investigational. Not commercially available as of mid-2026.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Imapextide is investigational as of mid-2026 and not FDA-approved. PBH management requires bariatric medicine specialty care.

Timeline of Effects

Common Questions

Who Imapextide Is NOT For

Drug & Supplement Interactions

Imapextide should not be co-administered with GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide, etc.) due to opposite mechanisms. DPP-4 inhibitors are mechanistically contraindicated (they amplify endogenous GLP-1 that imapextide is designed to block). For PBH patients on dietary management plus possibly acarbose or diazoxide, those combinations may be appropriate adjuncts.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions